^
    Back
    Association details:
    Biomarker:ALK rearrangement + ALK R1275Q + TP53 mutation
    Cancer:Neuroblastoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer

    Published date:
    08/22/2019
    Excerpt:
    We investigated the VAF of resistance mutations in CTCs from 14 ALK-rearranged patients progressing on crizotinib...The ALKR1275Q mutation (VAF, 8%) described as activating in patients with neuroblastoma was found in a CTC specimen of P32 but not in the tumor biopsy, as well as nine “off-target” mutations including TP53 (VAF range, 3%–25%; ref. 50).
    DOI:
    10.1158/1078-0432.CCR-19-1176